providing different information from that provided by PD 20 histamine. Background -Inhaled adenosine mono- (Thorax 1997;52:239-243) phosphate (AMP) is thought to cause bronchoconstriction in asthmatic patients indirectly through mast cell mediator re-Keywords: adenosine monophosphate, histamine, bronchial responsiveness.

protection afforded by terbutaline on AMP and methacholine in 12 subjects was statistically FEV 1 was measured with a dry bellows spirometer (Vitalograph, Buckingham, UK) as the significant. higher of two successive readings within 100 ml. The PD 20 AMP and histamine were determined using a breath activated dosimeter    (MEFAR, Brescia, Italy). The nebuliser was PD 20 values for histamine and AMP were log set to nebulise for one second with a pause of transformed for analysis and geometric mean six seconds at a pressure of 22 lb/in (152 kPa). values are given. Differences in PD 20 were Histamine and AMP (Sigma, Poole, Dorset, measured in doubling doses (DD). The pro-UK) were dissolved freshly in saline to tective effect of terbutaline on histamine and produce a doubling concentration range of AMP was measured in doubling doses for each 0.115-118 M for AMP and 0.021-21 M for subject by calculating histamine. FEV 1 was measured one minute after each dose. Inhalation was stopped when log PD 20 (terbutaline) -log PD 20 (placebo) log 2 the FEV 1 had fallen by 20% or more, when subjects had inhaled the highest dose of constrictor agent, or if side effects occurred. The and compared by paired t test. The repeatability PD 20 value was determined by interpolation of histamine and AMP PD 20 measurements was between the last two points on the log doseassessed as the limits of agreement according to response plot. Extrapolation was allowed for Chinn 11 as the mean (SD) difference in PD 20 one further dose.
difference × t 0.05 and converted to doubling doses. The limits of agreement for histamine and AMP PD 20 were then compared by un- paired t test. The study had a placebo controlled crossover
The limits of agreement for the first hisdesign. Subjects taking an inhaled steroid kept tamine and first AMP measurement were also the dose constant throughout the study. All computed as above after dividing PD 20 AMP studies were carried out at the same time of values by 17.8 since the mean PD 20 AMP was day and after subjects had withheld inhaled 17.8 times higher on average than the mean agonist treatment for at least eight hours.
PD 20 histamine value. Subjects attended the laboratory on four occasions within a week and after a two week interval on a further four occasions within a week. After resting for 15 minutes they inhaled Results Twenty subjects (nine men) aged 22-56 years placebo or terbutaline (500 g) by dry powder inhaler (Turbohaler) followed 15 minutes later were recruited. Nineteen completed all eight studies and one failed to return for the second by an inhaled histamine or AMP challenge. All four combinations of placebo and terbutaline set of four measurements. The mean initial FEV 1 was 2.62 litres (82% predicted). Details with the two challenges were given in random order on the four days before and on the four of the patients are presented in table 1.
On 20 of the 160 occasions a PD 20 could days after the two week interval. Treatment with placebo and terbutaline was double blind; not be obtained because patients did not bronchoconstrict with the highest dose of constrictor the nature of the histamine and AMP challenge was known to the investigator but not to the agent after terbutaline (n = 16; one for histamine and 15 for AMP) or because of coughsubjects.
The number of subjects studied was based ing after a lower dose of constrictor (n = 4). On these occasions the PD 20 value was censored on the study by O'Connor et al 8 in which a difference of 1.1 doubling doses between the to the highest dose of AMP or histamine given after extrapolation by one dose. 11 The pro-AMP compared with 2.11 and 2.15 DD for histamine). The mean difference between the tective effect of terbutaline was then assessed in two ways -in the 10 subjects who had no protective effect of terbutaline on histamine and AMP PD 20 was 0.58 DD (95% CI −0.28 censored values and by including all subjects and including the censored values. The mean to 1.44; p = 0.17) on the first occasion and 0.41 DD (95% CI −0.53 to 1.56; p = 0.37) PD 20 values on each occasion are given in table 2.
on the second. When the results from the 10 subjects with no censored values were analysed in the same way the difference between the protective effect of terbutaline against AMP  The agreement between the first and second and histamine induced bronchoconstriction remained non-significant on both the first (AMP PD 20 histamine values and between the first and second AMP values is shown in fig 1 2 .82 DD, histamine 2.64 DD; mean difference 0.18 DD; 95% CI −0.58 to 0.94; p = 0.6) according to the method of Bland and Altman. 12 The agreement limits for the two PD 20 and second occasion (AMP 3.14, histamine 2.46; mean difference 0.68 DD; 95% CI −0.94 histamine and two AMP measurements after placebo were from 3.06 to −3.5 and from 3.78 to 2.29 DD; p = 0.37).
There was no significant difference in the to −4.54 doubling doses, respectively, and the agreement limits for the two challenges did not change in PD 20 with terbutaline for either AMP (2.27 versus 2.22 DD) or histamine (1.9 versus differ significantly (p<0.05).
2.44 DD) between the 13 patients who were taking an inhaled corticosteroid and the seven who were not.    20    20  Following placebo the mean PD 20 AMP value was 17.8 times higher than the mean PD 20 histamine value (p<0.001). The relation be-Discussion tween the first PD 20 histamine and the first The mechanism underlying the broncho-PD 20 AMP values following placebo is shown constriction caused by inhalation of AMP in in fig 1, the AMP values having been divided patients with asthma is not certain but inby 17.8. The agreement limits for comparison creased release of mast cell mediators is probof the first histamine and first AMP PD 20 meas-ably involved. Adenosine and its synthetic urements after allowing for the 17.8-fold analogues such as AMP potentiate IgE dedifference in mean PD 20 values were 3.73 to pendent release of the preformed mediators −3.72 doubling doses.
histamine and hexosaminidase from rodent 13 and human 6 mast cells in vitro, and drugs that inhibit mast cell activation (sodium cro-    moglycate and nedocromil sodium) 14 15 or inTerbutaline had a slightly greater protective hibit the effect of mast cell products (the effect against AMP than histamine on both the selective H 1 receptor antagonists, terfenadine first and second occasions (terbutaline induced and astemizole [16] [17] [18] ) have been shown to protect changes in PD 20 were 2.70 and 2.56 DD for against AMP induced bronchoconstriction in both atopic 16 and non-atopic 17 subjects with asthma. Bronchoconstrictor prostanoids such though usually in normal subjects or patients tective effect against adenosine induced bronchoconstriction in asthma. 23 with mild asthma. To our knowledge, it has not been seen after 24 hours in patients with The bronchoconstrictor response to adenosine therefore involves one, or possibly two, asthma. Our studies were carried out at least a day apart as were the studies by O'Connor pathways which may be abnormally activated in asthma, suggesting that it may be a more et al 8 and as their patients had, if anything, milder asthma, tachyphylaxis would have been specific marker of asthma than bronchoconstrictor challenges such as histamine and more likely. Since we have also been unable to confirm that regular inhaled budesonide results methacholine. This could be of value for epidemiological studies where the lack of speci-in greater protection against AMP than histamine induced bronchoconstriction, 10 we conficity of histamine and methacholine in distinguishing asthma from other lung diseases clude that any difference in the ability of terbutaline or regular budesonide to provide limits their value. Using AMP to measure bronchial responsiveness would only be of value if greater protection against AMP is small in subjects with relatively mild asthma. the test was repeatable and this was questioned in a previous study. 10 The present study shows The agreement between a single PD 20 AMP and PD 20 histamine measurement after placebo no significant difference in the repeatability of the response to AMP when compared with that was similar to the repeatability of AMP and histamine after allowing for the 17.8 times of histamine challenge.
Previous studies have shown that a single higher mean values for AMP. This suggests that PD 20 AMP might not be adding anything dose of terbutaline (500 g) 7-9 or chronic treatment with budesonide 24 provide greater pro-further to the information given by PD 20 histamine in patients with asthma and that both tection against bronchoconstriction induced by AMP than that induced by methacholine. This are reflecting the same pathophysiological process in the airways. A study in children sugdifference has aroused interest since it may reflect drug effects other than airway smooth gested that PD 20 AMP was better able to distinguish asthma from COPD than methamuscle relaxation such as inhibition of mast cell mediator release by agonists and an anti-choline. 27 Further studies that include nonasthmatic patients are needed to determine inflammatory effect of inhaled corticosteroids. The protection against histamine induced whether PD 20 AMP provides greater specificity for asthma in adults in an epidemiological setbronchoconstriction in our study was similar to that seen with the same dose of terbutaline ting.
In conclusion, we have shown reasonable against methacholine challenge by O'Connor et al, 8 whereas the effect of terbutaline against agreement between PD 20 AMP and PD 20 histamine in 20 patients with asthma and similar AMP was less and the difference in protection against the two challenges was not statistically repeatability between AMP and histamine PD 20 values in these patients. We have been unable significant. The effect of terbutaline against AMP induced bronchoconstriction may have to confirm the previous finding of a greater protective effect of terbutaline against AMP been underestimated in our study since several subjects had censored PD 20 AMP values fol-compared with a challenge that is not mast cell dependent. These findings suggest that AMP lowing terbutaline, although the fact that the difference in the protective effect of terbutaline PD 20 gives similar information to histamine PD 20 in an asthmatic population; further field was not significant in the 10 subjects without a censored value argues against this. studies are needed to determine whether it is more specific for asthma in a population of The differences between our findings and those in previous studies could reflect differ-adults containing non-asthmatic patients. ences in asthma severity, or in the contribution of mast cell mediator release to broncho-We thank Ms H Tattersall for help with the randomisation of the study and Ms S Lewis for help with the analysis. constriction, or in previous treatment. The asthma severity appears to be similar to that in two of the previous studies 7 9 since patients however, in the relative protection of ter- 
